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Background: Type 2 diabetes mellitus is associated with a diverse range of pathologies. The aim of the study was
to determine the incidence of diabetes-related complications, the prevalence of coexistent chronic conditions and
to report multimorbidity in people with type 2 diabetes living in the Basque Country.
Methods: Administrative databases, in four cross sections (annually from 2007 to 2011) were consulted to analyse
149,015 individual records from patients aged ≥35 years with type 2 diabetes mellitus. The data observed were: age,
sex, diabetes-related complications (annual rates of acute myocardial infarction, major amputations and avoidable
hospitalisations), diabetes-related pathologies (prevalence of ischaemic heart disease, renal failure, stroke, heart failure,
peripheral neuropathy, foot ulcers and diabetic retinopathy) and other unrelated pathologies (44 diseases).
Results: The annual incidence for each condition progressively decreased during the four-year period: acute myocardial
infarction (0.47 to 0.40%), major amputations (0.10 to 0.08%), and avoidable hospitalisations (5.85 to 5.5%). The prevalence
for diabetes-related chronic pathologies was: ischaemic heart disease (11.5%), renal failure (8.4%), stroke (7.0%), heart
failure (4.3%), peripheral neuropathy (1.3%), foot ulcers (2.0%) and diabetic retinopathy (7.2%). The prevalence of
multimorbidity was 90.4%. The highest prevalence for other chronic conditions was 73.7% for hypertension, 13.8%
for dyspepsia and 12.7% for anxiety.
Conclusions: In the type 2 diabetes mellitus population living in the Basque Country, incidence rates of diabetes
complications are not as high as in other places. However, they present a high prevalence of diabetes related
and unrelated diseases. Multimorbidity is very common in this group, and is a factor to be taken into account to
ensure correct clinical management.
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The prevalence of type 2 diabetes is increasing worldwide
[1], probably due to a longer life expectancy of the general
population, a sedentary lifestyle and, above all, to increas-
ing obesity. Prevalence in Spain has been estimated at
13.8% (43% unknown diabetes) [2].
Diabetes is a chronic disease that leads to high morbid-
ity and mortality resulting from the complications that* Correspondence: edurne.almo@gmail.com
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article, unless otherwise stated.develop during its clinical course. Patients with diabetes
are twice as likely to develop cardiovascular disease com-
pared to the general population of the same age and sex,
and this risk remains the same after adjustments for other
traditional cardiovascular risk factors (CVRFs) [3]. More-
over, it is the leading cause of death in 80% of patients
with diabetes in comparison to 30% in the general
population [4]. This excess mortality is higher in women
than in men [3,5,6], and life expectancy is shortened by
7-10 years [7].
Incidences of chronic diabetes-related complications
have been related to poor metabolic control, diseaseCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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although these factors account for only a part of this
increased cardiovascular risk [6]. Early and aggressive
management of the disease is required to reduce cardio-
vascular events and improve prognosis [11] which, in the
Spanish context, is supported by means of the strategic
plan developed by the Spanish National Health System
(SNS) [12].
An association has been found between the increase in
comorbidities and a greater use of health services [13-15].
Many patients with type 2 diabetes also have other chronic
diseases interfering in the management of the disease, pa-
tient education and affecting health outcomes. Previous
studies have examined coexisting chronic pathologies in
patients with type 2 diabetes mellitus [16,17].
Therefore, this study aims to determine the prevalence
and incidence of diabetes-related complications, as well
as to provide a description of the multimorbidity of this
group in the Basque Country.Methods
The study protocol was approved by the Clinical Research
Ethics Committee of Euskadi (PI2014074), Spain. In-
formed consent was not obtained because patient health
records were made anonymous and deidentified prior to
analysis.
A descriptive study was performed which included
all patients with type 2 diabetes mellitus treated at
Osakidetza - the Basque Health Service. The Basque
Autonomous Community (BAC) has a public and uni-
versal health system, where the Department of Primary
Care acts as a gatekeeper to access to other departmental
services.
For this study, the demographic and clinical variables
information was obtained from the PREST database. In
such database, diagnoses are coded according to the
International Classification of Diseases (ICD-9-CM) [18],
and the coding system used for drugs is the Anatomical,
Therapeutic, Chemical (ATC) classification system [19].
PREST is the database of the Stratification Programme
which commenced in 2010 with the aim of classifying all
Basque citizens using the Johns Hopkins Adjusted Clinical
Groups (ACGs) case-mix system. This case mix enables
health problems to be identified from diagnoses and pre-
scriptions and patients to be categorised according to their
healthcare needs. PREST therefore combines information
from different sources (primary, specialty, emergency and
inpatient care) to obtain clinical variables, prescriptions
and procedures. A more detailed description is found in
previous publications [20].
The identification of all patients with type 2 diabetes
mellitus was based on selecting everybody who, according
to the PREST database, had been diagnosed with type2 diabetes mellitus or unspecified diabetes mellitus
(including its complications) at any point in their lives,
or who had been prescribed antidiabetic medication,
regardless of whether or not they had visited healthcare
services during the observation period (September 2007 -
August 2011). Excluded from this group were patients
who had been diagnosed with type 1 diabetes mellitus
during any contact with the services, or those whose diag-
nosis always corresponded to unspecified diabetes melli-
tus, but the only medication received was insulin.
Although type 2 diabetes can occur at any age [21], it is
more common after age 40; patients aged under 35 were
excluded.
Successive 12-month time periods were established
(year 1: from 01-09-2007 to 31-08-2008; year 2: from
01-09-2008 to 31-08-2009; year 3: from 01-09-2009 to
31-08-2010; year 4: from 01-09-2010 to 31-08-2011).
During each time period, a patient was considered as
presenting type 2 diabetes mellitus if the illness onset
date was prior to the established cut-off point (i.e. prior
to 01-09-2007, or prior to 01-09-2008 and so on), and
in addition, the patient had to have public insurance at
the start of the year (although not necessarily for the
whole year). Thus, the number of patients considered
as having type 2 diabetes mellitus was 116,295 in year
1; 123,991 in year 2; 130,554 in year 3 and 134,421 in
year 4. The total study population (people with type 2
diabetes mellitus in any of these years) was 149,015.Variables and analysis
The study variables were age, sex and existence of com-
plications and comorbidities (whether or not related to
type 2 diabetes mellitus). Hospital discharge records were
used to study the incidence of complications (Minimum
Basic Data Set [MBDS]) [22]. Hospital admission because
of acute myocardial infarction, major amputation or avoid-
able hospitalisations (Ambulatory Care Sensitive Conditions
[ACSC]) [23] was determined separately for each observa-
tion period.
To study the chronic diseases, a list of 52 health prob-
lems was developed and specific criteria were defined to
consider that particular disease as active during the period
from 01/09/2010 to 31/08/2011 by adapting a method-
ology previously reported by other authors [24]. In most
cases, criteria were based on considering that a person has
a chronic disease because they have been assigned the
corresponding diagnosis (for example, hypertension);
for some illnesses other criteria were applied: diagno-
sis or prescription of specific medications (e.g., for
hypothyroidism and Parkinson’s); repeated diagnosis
over several years (low back pain); any history of the
diagnosis together with prescription of specific drugs
in the previous year (asthma and epilepsy); diagnosis
Table 1 Incidence of complications of type 2 diabetes over the study period
Incidence (%)
Type 2 diabetes complications Year 1 Year 2 Year 3 Year 4 Percentage increase from year 1 to 4
Myocardial infarction 0.47 0.43 0.43 0.40 −13.64
Major amputations 0.10 0.10 0.09 0.08 −23.75
Avoidable hospitalisations (all causes) 5.85 5.66 5.41 5.50 −5.99
Avoidable hospitalisations because of DM 0.62 0.60 0.54 0.51 −18.14
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eral months (depression and anxiety); or repeated pre-
scriptions to treat the given health problem (treated
dyspepsia). Further information of this methodology
can be found in previous publications [25]. From such 52
health problems list, diabetes mellitus was excluded, and
such group was split in two parts: 1) Related chronic co-
morbidities, that , according to the bibliography [8], in-
cluded 7 pathologies: ischaemic heart disease, renal failure,
stroke, heart failure, peripheral neuropathy, foot ulcers
and diabetic retinopathy; and 2) unrelated chronic dis-
eases, that corresponds to the remaining 44 health
problems of the list.
The link to this database was feasible for 93% of patients
with type 2 diabetes mellitus in year 4; therefore, the num-
ber of people in which these pathologies was established
was limited to 126,894.
To analyse the data, the incidence or prevalence of the
aforementioned pathologies were estimated in the differ-
ent population strata according to age and sex. Logistic
regression determined the effect of the independent
variables (sex and age groups) on the coexistence of such
pathologies. To see whether there are differences betweenTable 2 Prevalence and incidence of diabetes-related complic
Type 2 diabetes complications Total (N = 134,421











Avoidable hospitalisations because of DM 0.51sexes in the distribution of diseases, the Pearson χ2 test
was performed. Reported P values under 0.05 were con-
sidered statistically significant.
Statistical calculations were performed using Stata Data
Analysis and Statistical Software, Release 12 (StataCorp,
LP, College Station, TX, USA).Results
Evolution of the incidence of diabetes-related
complications
It was observed that the incidence of diabetes-related
complications has declined over the past four years. The
number of major amputations performed (-23.8%) and the
number of acute myocardial infarctions (-13.6%) have
decreased, among others. All this information is con-
tained in Table 1.Diabetes-related chronic pathologies
For year 4 of the study, the chronic complications of pa-
tients with type 2 diabetes are shown in Table 2. It was
observed that the prevalence of renal failure, heart fail-
ure, peripheral neuropathy, and foot ulcers was higher inations in year 4 (September 2010- August 2011)
Prevalence (%)














Table 3 Logistic regressions of diabetes-related complications adjusted according to age and sex
Ischaemic heart
disease
Renal failure Stroke Heart failure Peripheral
neuropathy






Features OR P value OR P value OR P value OR P value OR P value OR P value OR P value OR P value OR P value OR P value
Sex
Males (ref) 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0
Females 0.4 <0.001 0.7 <0.001 0.7 <0.001 0.9 <0.001 1.1 0.033 0.9 0.113 1.0 0.943 0.7 <0.0001 0.5 <0.001 0.5 0.004
Age bands
Range 35-39 (ref) 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 (ref)
Range 40-44 2.5 0.013 1.1 0.779 2.7 0.111 4.1 0.181 1.7 0.317 1.3 0.572 1.0 0.854 1.1 0.681 1.0(ref)
Range 45-49 4.5 <0.001 1.5 0.181 5.6 0.004 7.8 0.043 2.1 0.115 1.6 0.348 1.7 0.003 0.9 0.73 0.98 0.976
Range 50-54 8.2 <0.001 1.6 0.085 7.7 <0.001 9.0 0.029 2.6 0.040 2.3 0.077 1.6 0.004 1 0.881 1.4 0.481 1.0 (ref)
Range 55-59 10.7 <0.001 2.2 0.004 10.3 <0.001 14.2 0.008 2.6 0.040 1.9 0.153 1.9 <0.001 1.1 0.718 1.3 0.61 1.3 0.678
Range 60-64 11.6 <0.001 3.0 <0.001 14.5 <0.001 19.5 0.003 2.8 0.022 2.5 0.045 2.1 <0.001 1.2 0.353 1.2 0.705 0.5 0.365
Range 65-69 13.9 <0.001 4.1 <0.001 18.8 <0.001 23.8 0.002 3.0 0.015 2.6 0.038 2.2 <0.001 1.4 0.114 1.2 0.747 1.6 0.445
Range 70-74 16.8 <0.001 6.1 <0.001 25.5 <0.001 35.8 <0.001 3.0 0.016 3.5 0.006 2.2 <0.001 1.8 0.006 1.5 0.349 3.1 0.069
Range 75-79 21.0 <0.001 10.0 <0.001 33.6 <0.001 62.6 <0.001 3.0 0.015 4.8 0.001 2.3 <0.001 2.8 <0.001 2.2 0.086 2.2 0.217
Range 80-84 23.7 <0.001 14.2 <0.001 48.1 <0.001 94.9 <0.001 3.0 0.015 6.9 <0.001 2.2 <0.001 3.8 <0.001 2.5 0.044 3.8 0.03
Range 85 and over 26.5 <0.001 21.6 <0.001 65.5 <0.001 156.3 <0.001 2.2 0.083 10.5 <0.001 1.5 0.011 5.5 <0.001 3.5 0.007 3.7 0.037
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heart disease and stroke was higher in men than women.
When logistic regressions were applied, women with
type 2 diabetes mellitus presented a lower probability
than men of suffering from ischaemic heart disease,
renal failure, stroke, heart failure, foot ulcers and retin-
opathy (approximately 58%, 30%, 35%, 14%, 6% and 1%
less respectively), and all the analyses were statistically
significant except the last two chronic diseases men-
tioned (Table 3). In addition, women also presented a
32% lower probability of suffering avoidable hospitalisa-
tions (P < 0.001), a 50% lower probability of myocardial
infarction (P < 0.001) and a 45% lower probability for
major amputations (P = 0.004) than men. The only
condition where females presented a higher probabil-
ity (10.4%) of suffering than males was peripheral
neuropathy.
Age was also an important factor in the complications
(Table 3). The probability of suffering from one of these
complications increased significantly with age. Since in
myocardial infarction there are no people in the age
group 35-39, the following group was taken as reference;
the same applied to major amputations where the 50-54
age group was taken as reference. Compared to the 35-
39 age group, the over 85 age group was not statistically
significant for peripheral neuropathy. Moreover, for
myocardial infarction and major amputations only age
over 79 years was statistically significant for the analysis.Unrelated chronic conditions
The relationship with multimorbidity in year 4 of the
study for this group of patients is shown in Table 4. It
shows the percentage of patients in relation to the
number of pathologies they suffer, where 1 represents
diabetes type 2, 2 represents diabetes plus one chronic
disease, and so on. For both sexes it is observed thatTable 4 Number (proportion) of people with type 2
diabetes in relation to number of chronic diseases
Number of
pathologies
Total N (%) Male (N) Female (N)
1 12,031 (9.64) 7,849 (11.65) 4,182 (7.28)
2 26,946 (21.59) 15,676 (23.27) 11,270 (19.63)
3 27,312 (21.89) 14,683 (21.80) 12,629 (21.99)
4 21,230 (17.01) 10,795 (16.03) 10,435 (18.17)
5 14,664 (11.15) 7,224 (10.73) 7,440 (12.96)
6 9,139 (7.32) 4,487 (6.66) 4,652 (8.10)
7 5,749 (4.61) 2,779 (4.13) 2,970 (5.17)
8 3,446 (2.76) 1,690 (2.51) 1,756 (3.06)
9 1,992 (1.60) 1,021 (1.52) 971 (1.69)
10 or more 2,272 (1.82) 1,152 (1.71) 1,120 (1.95)two chronic diseases plus diabetes is the most common
combination. Almost 30% suffer from five or more
chronic diseases, and only 9.64% are free from other
pathologies.
Table 5 shows the prevalence of patients with type 2
diabetes, in general and according to sex, who suffer
from each of the 44 chronic diseases. Overall, the most
common diseases were hypertension (73.71%), dyspepsia
(13.81%), anxiety (12.75%), and degenerative joint disease
(11.72%). Among men the study revealed hypertension
(73.23%), prostatic hypertrophy (13.48%), atrial fibrillation
(12.15%) and COPD (12.09%) as the most common dis-
eases. Among women, the most prevalent conditions
were hypertension (73.54%), anxiety (12.75%), dyspepsia
(16.7%), degenerative joint disease (15.79%) and depres-
sion (14.78%). In patients with type 2 diabetes, no sex
differences for deafness (P = 0.07), immunological disease
(P = 0.25), chronic haematological disease (P = 0.09), epi-
lepsy (P = 0.46), chronic sinusitis (P = 0.89), learning
disability (P = 0.12) and ADHD (P = 0.31) were found.Discussion
Compared with other studies [26-28], we have obtained
lower rates of incidence for avoidable hospitalisations,
acute myocardial infarction and major amputations.
Moreover, as Vamos et al. [26], we have found that sex
was statistically significant for major amputation and
women presented a 45% lower probability than men of
being affected; the same applied to myocardial infarc-
tion (50% lower) and for avoidable hospitalisations
(32% lower).
In this study, we could see a reduction in the rate of
incidence of diabetes-related complications from 2007 to
2011. Adequate control of type 2 diabetes risk factors is
high in the Basque population [29]. In addition, other
studies have reported decreasing incidence of several
complications such as amputations [26,30,31] and pre-
ventable hospitalisations [32]. Vamos et al. [26] found
that the incidence for amputations decreased by 9.1%
in the four-year study period and a series of studies.
The outcomes of chronic complications, such as
stroke and ischaemic heart disease are similar to those
observed in other Spanish studies [33,34]. Men had a
higher prevalence than women of ischaemic heart dis-
ease and stroke. Indeed, sex was statistically significant
for all analyses except foot ulcers and retinopathy;
women reported approximately a 58%, 30%, 35% and
14% lower probability than men of developing ischaemic
heart disease, renal failure, stroke and heart failure, re-
spectively. Furthermore, the probability of suffering one of
these complications increased significantly with age.
The prevalence of two or more chronic diseases in
addition to type 2 diabetes mellitus was 68.8%. This was
Table 5 Prevalence of 44 chronic diseases in type 2 diabetes patients
Chronic disease Overall (%) Males (%) Females (%) Differences between sexes
Hypertension 73.71% 73.23% 73.54% <0.001
Dyspepsia 13.81% 11.36% 16.70% <0.001
Prostatic hypertrophy — 13.48% — —
Anxiety 12.75% 8.54% 18.10% <0.001
Degenerative joint disease 11.72% 7.79% 15.79% 0.002
Atrial Fibrillation 10.40% 12.15% 8.54% <0.001
Depression 9.77% 5.47% 14.78% <0.001
Malignant neoplasms 8.86% 11.17% 6.96% <0.001
Chronic heart disease, other 8.57% 10.77% 6.09% <0.001
Emphysema, chronic bronchitis, COPD 8.23% 12.09% 4.50% <0.001
Hypothyroidism 6.22% 2.31% 11.31% <0.001
Low back pain 5.82% 4.34% 7.65% <0.001
Dementia 5.05% 4.17% 5.80% <0.001
Osteoporosis 4.46% 0.83% 8.26% <0.001
Gout 3.72% 5.75% 1.44% <0.001
Deafness 3.50% 3.52% 3.41% 0.071
Asthma (currently under treatment) 3.26% 1.99% 4.78% <0.001
Chronic hepatopancreatic diseases 3.25% 3.91% 2.29% <0.001
Diverticular disease 2.80% 2.58% 3.03% <0.001
Peripheral vascular disease 2.50% 3.96% 0.97% <0.001
Rheumatoid arthritis and others 2.40% 2.10% 2.78% <0.001
Errors of metabolism and chromosomopathies 2.15% 2.51% 1.69% <0.001
Parkinson’s disease 1.88% 1.83% 1.99% <0.001
Muscular dystrophy or paralysis 1.53% 1.73% 1.33% 0.005
Schizophrenia 1.50% 1.24% 1.81% <0.001
Chronic constipation 1.07% 1.04% 1.17% <0.001
Alcohol abuse 1.00% 1.46% 0.40% <0.001
Viral Hepatitis 0.81% 0.84% 0.71% <0.001
Psoriasis or eczema 0.76% 0.87% 0.63% <0.001
Immunological diseases 0.63% 0.66% 0.63% 0.245
Irritable bowel syndrome 0.60% 0.38% 0.87% <0.001
Bronchiectasis 0.59% 0.75% 0.47% 0.003
Chronic Haematological Diseases 0.58% 0.60% 0.59% 0.085
Epilepsy (currently under treatment) 0.55% 0.58% 0.53% 0.457
Inflammatory bowel disease 0.50% 0.52% 0.47% 0.040
Post-transplant state 0.37% 0.44% 0.26% <0.001
Chronic Sinusitis 0.26% 0.25% 0.28% 0.891
Learning Disabilities 0.13% 0.11% 0.17% 0.115
HIV 0.12% 0.15% 0.06% <0.001
Migraine 0.11% 0.04% 0.23% <0.001
Substance Abuse 0.11% 0.14% 0.05% <0.001
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Table 5 Prevalence of 44 chronic diseases in type 2 diabetes patients (Continued)
Multiple sclerosis 0.07% 0.05% 0.10% 0.033
Anorexia, bulimia 0.03% 0.01% 0.06% <0.001
ADHD 0.005% 0.002% 0.01% 0.311
Stratified by sex and all prevalence is adjusted by age and sex (in overall case). Statistically significant differences are those with P value <0.05.
ADHD: Attention Deficit Hyperactivity Disorder; COPD: Chronic Obstructive Pulmonary Disease; HIV: Human Immunodeficiency Virus.
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care patients (68.4%) [17]. In our analysis of sex-related
differences for multimorbidity, men presented a greater
prevalence of hypertension, prostatic hypertrophy, atrial
fibrillation and COPD; women presented greater preva-
lence of hypertension, anxiety, dyspepsia, degenerative
joint disease and depression.
Our study has several strengths. First, Osakidetza is a
healthcare system with universal coverage. This makes it
possible for our study to include almost all the popula-
tion with type 2 diabetes in the geographical area under
study; selection bias is thus avoided. Second, it makes
use of a database which contains information from pri-
mary care, specialty care, hospital care, and prescrip-
tions. This is relevant, as other authors have established
that the use of just one source can produce inaccurate
calculations [35,36], while the complementary use of
various sources contributes to a better description of the
persons’ health problems [37].
The study limitations correspond to the use of adminis-
trative databases, which only contain information about
patients who seek healthcare. Therefore, the prevalence of
complications can only reflect known cases and exclude
cases not known by the patient or healthcare personnel.
Type 2 Diabetes Mellitus is a disease associated with
reduced quality of life due to associated chronic compli-
cations that develop throughout the natural develop-
ment of the disease. Adequate metabolic control may
help reduce the risks of complications over the long-
term. The epidemiological information available in the
BAC gives an idea of its importance and the growing im-
pact on the population and health services.
This study provides relevant epidemiological informa-
tion about the prevalence and incidence of diabetes-
related complications, in addition to, multimorbidity in
this patient group. Moreover, it has been utilised to
confirm differences between sex and age that could be
employed to define interventions focused on certain pa-
tient profiles. Moreover, it could even be used as a sup-
port for a future diabetes registry to improve the
disease monitoring and research in our community.
Conclusions
The high prevalence of multimorbidity and the diversity
of chronic conditions complicate disease management inthis group and show the need for a holistic approach in
its clinical care and education. Furthermore, the need to
educate patients regarding self-care and to pay special
attention to the implications of polypharmacy must be
emphasised [38]. In the same way, there is a need to
perform further research to reach a consensus on de-
veloping Clinical Practice Guidelines focused on pa-
tients with multiple pathologies, thereby reducing the
risk of inappropriate clinical management and patient
safety issues such as drug interactions.
Chronic complications of diabetes have a relevant im-
pact on the population with type 2 diabetes. Therefore,
an expansion of epidemiological knowledge and im-
proved disease monitoring should be a public health
priority, to address the social and health implications
and to develop interventions that enable better man-
agement of these patients.
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